Group Director, AstraZeneca Oncology
Oncology
Dr. Gregory A. Curt, MD
|
|
Give Review
Gregory Curt works in the field of Oncology. He went to medical school at University of Rochester School of Medicine and Dentistry. Gregory A. Curt, MD is also published. He has 63 publications published. The lastest publication: "Inhibition of nucleic acid synthesis by the di-n-butyl ester of methotrexate.'
Publications
- Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.
- Step change in safe harbors: public-private partnerships.
- One in five cancer clinical trials is published: a terrible symptom--what's the diagnosis?
- A "Masterpiece": the life of Paul Calabresi, M.D. (1930-2003).
- SEER: Report (card) to the nation.
- Cancer fatigue: the way forward.
- Clinical trial design for target-based therapy.
- High-dose carboplatin in refractory ovarian cancer patients.
- Incorporation of iododeoxyuridine into neoplastic DNA: a fraudulent magic bullet?
- Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study.
- A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma.
- 5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
- A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration.
- Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity.
- Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.
- Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
- Use of complementary medicine by adult patients participating in cancer clinical trials.
- Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors.
- Use of complementary medicine by adult patients participating in HIV/AIDS clinical trials.
- Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.
- The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2.
- Terrorism and cancer.
- [Fatigue syndrome caused by malignant tumor. An increasing priority in patient care].
- Fatigue in cancer.
- Impact of fatigue on quality of life in oncology patients.
- The evolving face of palliative care in cancer medicine.
- Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.
- Issues in antiemetic therapy.
- The use of animal models in cancer drug discovery and development.
- Reversible rapidly progressive renal failure with nephrotic syndrome due to fenoprofen calcium.
- Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro.
- Reversible acute pulmonary edema due to uncontrolled hyperglycemia in diabetic individuals with renal failure.
- Surgical oncology research development: the perspective of the National Cancer Institute.
- Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone.
- Gene amplification in drug resistance: of mice and men.
- Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.
- Symposium on cellular resistance to anticancer drugs. Introduction.
- Warning on immunoaugmentative therapy.
- Cancer chemotherapy. Progress and expectations, 1984.
- The pharmacology and clinical use of methotrexate.
- A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
- Evidence for multidrug-resistant cells in human tumor cell populations.
- Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes.
- Synthesis and retention of methotrexate polyglutamates by human small cell lung cancer.
- Drug resistance in cancer.
- Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique.
- Measuring levels of methotrexate.
- Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs.
- A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
- Inhibition of nucleic acid synthesis by the di-n-butyl ester of methotrexate.
- Risk of acute renal failure following angiography in the elderly: a case report.
- Carboplatin for advanced colorectal carcinoma: a phase II study.
- Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512).
- Competitive protein-binding assay for trimetrexate.
- Bone marrow transplantation: current perspectives and future directions.
- Immunoaugmentative therapy. A primer on the perils of unproved treatments.
- Skin reactions induced by trimetrexate, an analog of methotrexate.
- Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.
- Antimetabolites.
- Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate.
- Polyglutamation of methotrexate. Is methotrexate a prodrug?
- A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
Schools
University Of Rochester
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Beth Israel Deaconess Medical Center -
University of Rochester School of Medicine and Dentistry